Neovacs

Vaxconsulting

Peptinov Sas

Neovacs S.a.

Biovacs, Inc.

Peptinov

Jean-François Zagury

Daniel Zagury

Jay F Rappaport

Matthieu Montes

Hélène Le Buanec

Lucille Desallais

Miguel Carcagno

Rojo Ratsimandresy

The present invention relates to a pharmaceutical composition comprising as active substance, at least one compound comprising, or consisting of, a polypeptide which comprises, or consists of, at least 11 contiguous amino acids selected from X-S-D-I-F-X-G-E-P-X-L-X-P-X-X-X-X-X-Q-L (SEQ ID NO: 13).

Method of vaccination for limiting articular inflammation in rheumatoid arthritis and multiple sclerosis by administering IL-23 peptides

An immumogenic polypeptide for inducing antibodies that neutralize the immunosuppressive and/or angiogenic activity of an E7 protein from Papillomavirus, wherein said immunogenic polypeptide consists of an E7 protein from Papillomavirus that has been inactivated so as to eliminate at least 70% of the immunosuppressive and/or angiogenic activity of the non-inactivated E7 protein. The inactivation is effected by physical and/or chemical treatments and/or by modification of the amino acid sequence of the polypeptide.

Use of immunogenic immunosuppressive and/or angiogenic proteins which have been rendered inactive, process for their preparation and pharmaceutical or vaccinal uses

Peptide of a size comprised between 5 and 40 amino acids, originating from a cytokine, in which at least one of its amino acids comprises at least one of its atoms separated by a distance d of less than 5 angstr&#xf6;ms from an atom of the receptor corresponding to said cytokine, the spacing d being evaluated on the basis of structural data, derivatives, immunogenic compounds comprising them, use of a peptide or peptide derivative or immunogenic compound for the preparation of a curative or preventative medicament intended for the treatment or prevention of diseases linked to an excess or to the presence of cytokines or for the treatment of an auto-immune disease and pharmaceutical compositions which contain at least one abovementioned peptide or peptide derivative or immunogenic compound as active ingredient.

Peptides for active anti-cytokine immunization

The invention concerns a derivative of viral regulatory protein or a fragment of viral regulatory protein or of the alpha interferon or a fragment of alpha interferon, which is carboxymethylated, a method for preparing, use of the resulting product in a method of treatment for the human or animal body, a pharmaceutical composition and a vaccine containing as active principle, at least one of the carboxymethylated proteins or fragments.

Chemically modified cytokines

This invention relates to retroviral regulatory proteins or fragments thereof, or interferon alpha protein or fragments thereof, which are carboxymethylated. This chemical modification leads to new proteins or fragments which are biologically inactive but preserve their immunogenicity (toxoids). These proteins or fragments thereof, or interferon alpha or fragments thereof, can be utilized in the treatment and prevention of retroviral infections. The invention also relates to a pharmaceutical composition comprising at least one carboxymethylated protein or fragment of the invention, together with a pharmaceutically acceptable carrier. The invention also relates to a vaccine comprising at least one of the carboxymethylated proteins or fragments of the invention, together with an immunologically acceptable carrier. The invention also relates to a process for obtaining an immunogenic yet not toxic retroviral regulatory protein or fragment, or interferon alpha or fragment. The invention also relates to a method of inducing an immune response in a mammal, comprising administering the vaccine of the invention to a mammal in an immunologically effective amount.

Carboxymethylated retroviral regulatory proteins and interferon-&#x3b1;

The present invention concerns a chemically modified TNF-&#x3b1;, and a pharmaceutical composition and a vaccine composition containing the chemically modified TNF-&#x3b1; which are useful for combating overproduction of native TNF-&#x3b1;.

Growing community of inventors

Paris, France

Jean-François Zagury